EQ - Equillium COVID-19 Data And Other News: The Good Bad And Ugly Of Biopharma
Equillium Reports Positive Data for COVID-19 Drug Trial
Equillium Inc. (EQ) reported positive data for its COVID-19 drug itolizumab. The data showed that the drug candidate was useful in lowering the risk of mortality in patients suffering from coronavirus. The results were declared by its partner Biocon Limited from a clinical trial conducted in India.
The trial was a randomized, controlled, open-label study with 30 hospitalized patients spread across four hospitals in India. These patients suffered from moderate to severe ARDS. Out of these 30 patients, 20 were randomized to be administered itolizumab plus best